Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.50 USD
Change Today -0.17 / -0.50%
Volume 129.6K
PMC On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

pharmerica corp (PMC) Key Developments

PharMerica Reportedly Can Be The Target Of The Next Big Healthcare Deal

People in the investment banking and healthcare industries speculate that PharMerica Corporation (NYSE:PMC) will soon be acquired. PharMerica's shares are up more than 50% in 2015.

PharMerica Corporation Enters into Voluntary Settlement Agreement with Department of Justice and Drug Enforcement Agency

PharMerica Corporation announced that it has reached a voluntary settlement with the Department of Justice (DOJ) and with the Drug Enforcement Agency (DEA) related to a previously disclosed investigation into the dispensing of controlled substances at certain of the company’s pharmacies. The settlement contains no allegations or findings that controlled substances were diverted or that any patient was harmed. Under the terms of the Settlement Agreement, PharMerica has agreed to pay $31.5 million to the federal government. The company is fully reserved for that amount. As part of the settlement, PharMerica voluntarily entered into a three-year Memorandum of Agreement (MOA) with the DEA and a five-year Corporate Integrity Agreement (CIA) with the Office of the Inspector General (OIG). The company changed its operating policies in 2010 to enhance procedures related to the dispensing of controlled substances. The MOA and the CIA will further enhance PharMerica’s long-standing compliance programs.

PharMerica Corporation Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Second Quarter and Full Year of Fiscal 2015

PharMerica Corporation reported unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of USD 511.6 million against USD 452.2 million a year ago. Operating income was USD 16.8 million against USD 10.3 million a year ago. Income before income taxes was USD 15.4 million against USD 7.8 million a year ago. Net income was USD 9.6 million against USD 4.8 million a year ago. Diluted net income per share was USD 0.31 against USD 0.16 a year ago. Net cash provided by operating activities was USD 44.3 million against USD 4.4 million a year ago. Purchase of equipment and leasehold improvements was USD 4.6 million against USD 6.0 million a year ago. Adjusted EBITDA was USD 37.4 million against USD 29.7 million a year ago. Adjusted diluted earnings per share were USD 0.48 against USD 0.37 a year ago. The increase in revenue was driven by 2014 acquisitions, growth in both specialty oncology and specialty infusion, and branded drug inflation. The increase in cash from operating activities was due primarily to the USD 50.0 million in ABDC drug purchase payments withheld, the corporation’s inventory purchasing strategy, and an increase in net income which were partially offset by an increase in ABDC rebates receivable. The company reaffirmed earnings guidance for the year 2015. For the year, the company expects revenue in the range of USD 1.950 billion to USD 2.050 billion; adjusted diluted earnings per share in the range of USD 1.55 to USD 1.65; and adjusted EBITDA in the range of USD 137 million to USD 142 million. For the second quarter of 2015, the company expects revenue in the range of USD 465 million to USD 495 million, adjusted diluted earnings per share in the range of USD 0.30 to USD 0.34 and adjusted EBITDA in the range of USD 30 million to USD 32 million.

PharMerica Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM

PharMerica Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Gregory S. Weishar, Chief Executive Officer, President and Director.

PharMerica Corporation to Report Q1, 2015 Results on May 07, 2015

PharMerica Corporation announced that they will report Q1, 2015 results at 10:00 AM, US Eastern Standard Time on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PMC:US $33.50 USD -0.17

PMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $94.29 USD +0.09
SunLink Health Systems Inc $1.57 USD +0.06
View Industry Companies
 

Industry Analysis

PMC

Industry Average

Valuation PMC Industry Range
Price/Earnings 88.3x
Price/Sales 0.5x
Price/Book 2.1x
Price/Cash Flow 29.9x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMERICA CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.